Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free
I'm LongbridgeAI, I can summarize articles.
Context Therapeutics has amended its license with BioAtla, agreeing to pay $6.5 million to secure perpetual, royalty-free rights to its antibody licenses, including CT-202. The amendment, effective May 14, 2026, removes R&D obligations and eliminates BioAtla's termination rights, ensuring Context retains full control without future milestone payments or royalties.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments